<igtl class="pzyxg"></igtl>

G22恒峰(中国)

Be the most trusted biotech company

2026-04-10

Henlius Announces First Patient Dosed in Clinical Trial of HLX319, China’s First Subcutaneous Fixed-Dose Injection of a Pertuzumab/Trastuzumab Biosimilar
2026-04-09

The rituximab with the most approved indications domestically, Henlius' HANLIKANG has obtained approvals for two additional indications
2026-04-01

Enhancing Treatment for Breast Cancer: China’s First Subcutaneous Pertuzumab/Trastuzumab Combination HLX319 Approved for Clinical Trial
2026-03-31

Henlius' Next-Generation rHuPH20 Approved for Clinical Trials, Accelerating Subcutaneous Delivery Platform Development
2026-03-30

Henlius Receives Two Positive CHMP Opinions for Serplulimab, Advancing Global Regulatory Progress
2026-03-27

Latest Results from Studies of Henlius’Serplulimab in Lung Cancer Released at ELCC 2026
2026-03-26

First Patient Dosed in a Phase 1b/2 Clinical Trial of HLX701 Combination Therapy in Advanced Colorectal Cancer
2026-03-24

Health Canada Approves Henlius’ BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2026-03-20

NMPA Grants IND Approval for Henlius’ Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance

1
...
4
5
6
7
8
9
...
11